 BiondVax Pharmaceuticals Ltd. Nasdaq: BVXV, a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal influenza vaccine candidate, today announced its first quarter financial results for the quarter ended March 31, 2020. 